Earnings call transcript: Fisher & Paykel Healthcare posts strong H2 2026 results

Fisher & Paykel Healthcare reported strong FY2026 results, with operating revenue up 14% to NZD 2.3 billion, NPAT up 24% to NZD 468.5 million, and gross margin improving 122 bps to 63.7%. Operating cash flow rose 21% to NZD 663 million and the total dividend increased 22% to NZD 0.52 per share, but shares slipped 0.43% to 27.53 amid tariff and FX headwinds. Management guided FY2027 revenue to NZD 2.45 billion-NZD 2.57 billion and NPAT to NZD 500 million-NZD 550 million, while flagging a 50 bps gross margin drag from tariffs and Middle East-related supply costs.

Analysis

The key read-through is not the earnings beat itself but the mix of cyclical insulation and self-help. This is a business proving it can grow through a tariff regime, FX drag, and shipping disruption, which implies the market has underappreciated the durability of clinical adoption and pricing discipline. The more important second-order effect is that management is explicitly signaling willingness to absorb cost shocks rather than reprice; that preserves volume, but it also means margin recovery will be driven by mix, manufacturing leverage, and supply-chain arbitrage rather than an easy customer pass-through.

The FY27 setup looks asymmetrical: the company is effectively buying time via hedging, inventory, and plant flexibility, but it is also admitting that some of the recent hardware acceleration was front-loaded demand. That creates a near-term deceleration risk in hospital hardware and some home-care replacement categories, which can mask ongoing consumables strength. If the street extrapolates the recent growth rate, consensus is probably too high for revenue but too low for gross margin resilience if freight and tariffs normalize faster than expected.

For competitors, this is a quiet negative for lower-scale respiratory device players that cannot absorb tariff friction or sustain R&D intensity. The broader healthcare supplier chain also sees a signal that clinical guideline momentum can overwhelm seasonal noise, which raises the bar for rivals relying on demand cycles rather than product pull. The contrarian angle is that the stock’s weak reaction suggests investors are still discounting the durability of the new installed base; if hardware normalizes but consumables hold, the business mix actually improves over the next 6-18 months.

Key Decisions for Investors

• Long FPH / short a basket of smaller respiratory-device peers with weaker manufacturing flexibility over the next 3-6 months; thesis is that tariff and freight shocks compress weaker operators first while FPH protects volume and takes share.
• Buy FPH on any 5-8% pullback into the post-earnings digestion period; risk/reward improves if the market prices in hardware deceleration without recognizing consumables compounding.
• Sell call spreads on over-optimistic FY27 revenue continuation if available; upside is likely capped by hardware normalization, but gross margin should support the downside better than the top line.
• Pair long FPH against a logistics/freight-sensitive medtech manufacturer for 2H FY27; if Middle East disruption eases, FPH should re-rate on margin, while the peer’s less diversified supply chain remains exposed.
• For event-driven accounts, consider a 3-6 month collar structure on existing FPH longs: downside protection against a hardware rollover, while retaining participation in margin-led upside if freight and tariff headwinds fade.